Acta Crystallographica Section C

Crystal Structure Communications

ISSN 0108-2701

7-lodo-8-aza-7-deaza-2'-deoxy-adenosine and 7-bromo-8-aza-7-deaza-2'-deoxyadenosine

Frank Seela, ** Matthias Zulauf, * Hans Reuter *b and Guido Kastner *b

^aLaboratorium für Organische und Bioorganische Chemie, Institut für Chemie,
 Universität Osnabrück, Barbarastrasse 7, D-49069 Osnabrück, Germany, and
 ^bAnorganische Chemie II, Institut für Chemie, Universität Osnabrück, Barbarastrasse 7, D-49069 Osnabrück, Germany

Correspondence e-mail: fraseela@rz.uni-osnabrueck.de

Received 18 October 1999 Accepted 17 January 2000

The isomorphous structures of the title molecules, 4-amino-1-(2-deoxy- β -D-erythro-pentofuranosyl)-3-iodo-1H-pyrazolo-[3,4-d]pyrimidine, (I), $C_{10}H_{12}IN_5O_3$, and 4-amino-3-bromo-1-(2-deoxy- β -D-erythro-pentofuranosyl)-1H-pyrazolo[3,4-d]pyrimidine, (II), $C_{10}H_{12}BrN_5O_3$, have been determined. The sugar puckering of both compounds is C1'-endo ($^{1'}E$). The N-glycosidic bond torsion angle χ^1 is in the high-anti range [-73.2 (4)° for (I) and -74.1 (4)° for (II)] and the crystal structure is stabilized by hydrogen bonds.

Comment

Oligonucleotides containing 7-iodo-8-aza-7-deaza-2'-deoxyadenosine, (I), or 7-bromo-8-aza-7-deaza-2'-deoxyadenosine, (II) (Seela & Zulauf, 1998), show enhanced stability of duplexes with antiparallel (aps) chain orientation (Seela *et al.*, 1997; Seela & Zulauf, 1999). Purine skeleton numbering is used throughout the following discussion. The X-ray structures of the related 7-bromo- and 7-iodo-8-aza-7-deazaguanine 2'-deoxynucleosides show that the steric and stereoelectronic effects of the nucleobase are responsible for the high-*anti* conformation of the base and also for the sugarring conformation (Seela, Becher *et al.*, 1999). In the light of this, it was of interest to evaluate the crystal structures of the

7-halogeno-8-aza-7-deaza-2'-deoxyadenosines, (I) and (II), and compare them with that of the unsubstituted 8-aza-7-deaza-2'-deoxyadenosine (Seela, Zulauf *et al.*, 1999). Both

compounds can now be prepared in a one-pot reaction with increased yield compared with the two-step procedure (Seela & Zulauf, 1998). Compounds (I) and (II) crystallize isomorphously.

The ribonucleoside 8-aza-7-deazaadenosine (8-azatubercidin) exhibits a C1'-exo-C2'-endo conformation (Sprang et al., 1978), and for the unsubstituted 8-aza-7-deaza-2'-deoxy-4-adenosine a 2 ' T_3 ' (S-type sugar) sugar-ring conformation was determined (Seela, Zulauf et al., 1999). In contrast to this, an unusual C1'-endo (1 'E) sugar-ring conformation is observed for (I) and (II). This can be seen from the torsion angle ν_3 (C2'-C3'-C4'-O4') of -2.8 (4)° for (I) and -3.8 (4)° for (II), implying an almost planar arrangement of these four atoms, with a deviation of C1' from the least-squares planes of 0.488 (5) Å for (I) and 0.496 (5) Å for (II). The puckering amplitude τ_m and the pseudorotation phase angle P (Rao et al., 1981) for (I) are $\tau_m = 34.8$ (3)° and P = 309.4 (4)°, while for (II) $\tau_m = 35.0$ (3)° and P = 310.9 (4)°.

The orientation of the base relative to the sugar (syn/anti) is defined by the torsion angle χ^1 (O4'-C1'-N9-C4) (IUPAC-IUB Joint Commission on Biochemical Nomenclature, 1983); the preferred conformation around the N-glycosidic bond of a natural 2'-deoxynucleoside is usually in the anti range. It was shown that Coulomb repulsion between the non-bonding electron pairs of O4' and N8 of 8-azatubercidin (Sprang $et\ al.$, 1978), formycin (Prusiner $et\ al.$, 1973) and 7-halogeno-8-aza-7-deaza-2'-deoxypurines (Seela, Becher $et\ al.$, 1999) forces the N-glycosidic conformation into the high- $anti\ (-sc)$ range (Klyne & Prelog, 1960). Compounds (I) and (II) also adopt a high- $anti\ conformation\ [\chi^1 = -73.2\ (4)^\circ$ for (I) and $-74.1\ (4)^\circ$ for (II)].

The halogeno substituents possess a stereoelectronic effect (Seela, Becher *et al.*, 1999; Rosemeyer *et al.*, 1997); as a result, the torsion angle χ^1 is significantly lower compared with that for 8-aza-7-deaza-2'-deoxyadenosine [$\chi^1 = -106.3$ (2)°; Seela, Zulauf *et al.*, 1999] and the high-*anti* conformation is strengthened. Compared with (I) and (II), the 7-iodo-7-deaza-




Figure 1A perspective view of (I) showing the atomic numbering scheme. Displacement ellipsoids are drawn at the 50% probability level and H atoms are shown as spheres of small arbitrary size.

2'-deoxyadenosine adopts a C3'-exo (3'E) sugar conformation with an almost perfect anti orientation of the base $[\chi^1]$ -147.1 (8)°; Seela et al., 1996]. The high-anti conformation of (I) and (II) may be stabilized through van der Waals interactions resulting from the contact between N8 and C2' or one of its H atoms [N-C = 2.761 (5) Å and N-H = 2.45 Å for (I);N-C = 2.777 (5) Å and N-H = 2.47 Å for (II)]. Similar interactions were also observed for 8-azaadenosine (Singh & Hodgson, 1974) and 8-azatubercidin (Sprang et al., 1978).

Another intramolecular attraction was determined between the 7-halogeno substituent and one of the amino H atoms of (I) and (II). This hydrogen bond leads to a hindered rotation of the amino group. Therefore, two signals for the amino protons can be observed in the ¹H NMR spectra at ambient temperature. The proton signals become indistinguishable at a coalescence temperature of 340 K.




Figure 2 A perspective view of (II) showing the atomic numbering scheme. Displacement ellipsoids are drawn at the 50% probability level and H atoms are shown as spheres of small arbitrary size.

The exocyclic angle N8-N9-C1' is smaller than C4-N9-C1', by 6.3 (4) for (I) and by 5.6 (4) $^{\circ}$ for (II), as observed for other nucleosides adopting the high-anti conformation (Sprang et al., 1978; Prusiner et al., 1973). The conformation about the C4'-C5' bond of (I) and (II) is in the trans (+ap)range $[\gamma = 175.4 (3)^{\circ} \text{ for (I)}, 175.2 (3)^{\circ} \text{ for (II)}]$. The halogeno substituents of (I) and (II) lead to a lengthening of the glycosidic bond, while the other bond lengths and torsion angles of (I) and (II) are similar to those of 8-aza-7-deaza-2'deoxyadenosine (Seela, Zulauf et al., 1999).

Intermolecular hydrogen bonds formed by (I) and (II) generate a three-dimensional network and provide additional crystal stabilization (Tables 2 and 4).

The 8-aza-7-deazaadenine base of (I) and (II) is planar. The deviations of the ring C and N atoms from the least-squares plane are in the range of -0.031 (5)-0.043 (3) Å for (I) and -0.037 (5)-0.045 (3) Å for (II). The bulky iodo substituent of (I) lies -0.091 (6) Å and the bromo substituent of (II) -0.084 (6) Å out of the heterocyclic plane. For comparison, the iodo atom of 7-iodo-7-deaza-2'-deoxyadenosine is located -0.135 (14) Å out of the plane (Seela *et al.*, 1996).

Experimental

Compound (I) was prepared from 1-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-3-iodo-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine (Seela & Zulauf, 1998; 500 mg, 0.8 mmol) by treatment with saturated NH₃/MeOH (150 ml, 3:1 v/v) for 5 h at 363 K in an autoclave. The solvent was evaporated and the residue purified by flash chromatography on silica gel (column 10 × 3 cm, methanoldichloromethane 1:9). Crystallization from PrOH yielded colourless needles (yield 138 mg, 46%) which showed identical ¹H and ¹³C NMR data to those of a verified sample (Seela & Zulauf, 1998). Compound (II) was prepared from 3-bromo-1-[2-deoxy-3,5-di-O-(p-toluoyl)- β -D-erythro-pentofuranosyl]-4-methoxy-1Hpyrazolo[3,4-d]pyrimidine (Seela & Zulauf, 1998; 500 mg, 0.86 mmol) by treatment with saturated NH₃/MeOH (150 ml, 3:1 v/v) for 5 h at 363 K in an autoclave. The solvent was evaporated and the residue purified by flash chromatography on silica gel (column 10 × 3 cm, methanol-dichloromethane 1:9). Crystallization from ⁱPrOH yielded colourless needles (yield 148 mg, 52%) which showed identical ¹H and ¹³C NMR data to those of a verified sample (Seela & Zulauf, 1998).

Compound (I)	
Crystal data	_
$C_{10}H_{12}IN_5O_3$	$D_x = 2.029 \text{ Mg m}^{-3}$
$M_r = 377.15$	Mo $K\alpha$ radiation
Monoclinic, $P_{2_1}^2$	Cell parameters from 40
a = 9.259 (3) Å	reflections
b = 7.2787 (10) Å	$\theta = 5.08-17.82^{\circ}$
c = 9.767 (3) Å	$\mu = 2.607 \text{ mm}^{-1}$
$\beta = 110.29 (2)^{\circ}$	T = 293 (2) K
$V = 617.4 (3) \text{ Å}^3$	Needle, colourless
Z = 2	$0.55 \times 0.15 \times 0.15 \text{ mm}$
Data collection	
Siemens P4 diffractometer	$R_{\rm int} = 0.020$
$2\theta/\omega$ scans	$\theta_{\text{max}} = 27^{\circ}$
Absorption correction: ψ scan	$h = -11 \rightarrow 11$
(SHELXTL; Sheldrick, 1997a)	$k = -9 \rightarrow 9$
$T_{\min} = 0.445, T_{\max} = 0.704$	$l = -12 \rightarrow 12$
3057 measured reflections	3 standard reflections
1455 independent reflections (plus	every 97 reflections
1239 Friedel-related reflections)	intensity decay: none
2668 reflections with $I > 2\sigma(I)$	
Refinement	
Refinement on F^2	$(\Delta/\sigma)_{\text{max}} = 0.001$
$R[F^2 > 2\sigma(F^2)] = 0.026$	$\Delta \rho_{\text{max}} = 0.63 \text{ e Å}^{-3}$
$wR(F^2) = 0.069$	$\Delta \rho_{\min} = -0.65 \text{ e Å}^{-3}$
S = 1.036	Extinction correction: SHELXL97
2694 reflections	(Sheldrick, 1997b)
174 parameters	Extinction coefficient: 0.0102 (11)
Only H-atom <i>U</i> 's refined	Absolute structure: Flack (1983)
$w = 1/[\sigma^2(F_o^2) + (0.0411P)^2$	Flack parameter = -0.01 (2)

Selected geometric parameters (Å, °) for (I).

+ 0.4360P

where $P = (F_o^2 + 2F_c^2)/3$

N9-C1'	1.480 (4)		
C4-N9-C1'	127.5 (3)	N8-N9-C1'	121.2 (3)
C4-N9-C1'-O4' C2'-C3'-C4'-O4' C3'-C4'-C5'-O5' N8-N9-C1'-O4' C1'-C2'-C3'-C4'	-73.2 (4) -2.8 (4) 175.4 (3) 101.6 (4) 21.3 (4)	C2'-C1'-O4'-C4' C3'-C4'-O4'-C1' C3'-C4'-C5'-O5' O3'-C3'-C4'-C5' O4'-C4'-C5'-O5'	32.8 (3) -18.8 (3) 175.4 (3) 114.1 (3) 54.4 (4)

Table 2 Hydrogen-bonding geometry (Å, °) for (I).

$D-H\cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdot \cdot \cdot A$	D $ H$ $\cdot \cdot \cdot A$
N6-H61···O5′ ⁱ	0.86	2.17	2.907 (4)	143.2
N6−H62···I7	0.86	2.91	3.610 (3)	139.7
$O3'-H3'1\cdots N1^{ii}$	0.82	2.18	2.837 (4)	136.7
$O5'-H5'\cdots N3^{iii}$	0.82	2.18	2.940 (4)	154.5

Symmetry codes: (i) $-x, \frac{1}{2} + y, 1 - z$; (ii) 1 + x, y, 1 + z; (iii) $1 - x, y - \frac{1}{2}, 1 - z$.

Compound (II)

Crystal data

 $D_x = 1.827 \text{ Mg m}^{-3}$ $C_{10}H_{12}BrN_5O_3\\$ $M_r = 330.16$ Mo $K\alpha$ radiation Monoclinic, P2 Cell parameters from 35 a = 9.0930 (9) Åreflections b = 7.2595 (10) Å $\theta = 4.74 - 16.32^{\circ}$ c = 9.6369 (19) Å $\mu = 3.438 \text{ mm}^{-1}$ $\beta = 109.362 (11)^{\circ}$ T = 293 (2) K $V = 600.16 (16) \text{ Å}^3$ Needle, colourless $0.50 \times 0.12 \times 0.12 \text{ mm}$ Z=2

Data collection

Siemens P4 diffractometer $2\theta/\omega$ scans Absorption correction: ψ scan (SHELXTL; Sheldrick, 1997a) $T_{\min} = 0.497$, $T_{\max} = 0.662$ 2959 measured reflections (plus 1193 Friedel-related reflections) 2381 reflections with $I > 2\sigma(I)$ $\begin{aligned} R_{\rm int} &= 0.035 \\ \theta_{\rm max} &= 27^{\circ} \end{aligned}$

 $h = -11 \rightarrow 11$ $k = -9 \rightarrow 9$ $l = -12 \rightarrow 12$

3 standard reflections every 97 reflections intensity decay: none

Refinement

Refinement on F^2 $R[F^2>2\sigma(F^2)]=0.035$ $wR(F^2)=0.093$ S=1.052 2604 reflections 174 parameters Only H-atom U's refined $w=1/[\sigma^2(F_o^2)+(0.0529P)^2+0.2516P]$ where $P=(F_o^2+2F_c^2)/3$ $(\Delta/\sigma)_{\text{max}} = 0.001$ $\Delta\rho_{\text{max}} = 0.51 \text{ e Å}^{-3}$

 $\Delta \rho_{\min} = -0.54 \text{ e Å}^{-3}$ Extinction correction: *SHELXL*97

(Sheldrick, 1997b) Extinction coefficient: 0.0071 (17)

Extinction coefficient: 0.0071 (17) Absolute structure: Flack (1983) Flack parameter = -0.014 (11)

Table 3 Selected geometric parameters (Å, $^{\circ}$) for (II).

N9-C1'	1.473 (4)		
C4-N9-C1'	127.1 (3)	N8-N9-C1'	121.5 (3)
C4-N9-C1'-O4'	-74.1 (4)	C2'-C1'-O4'-C4'	32.5 (3)
C2'-C3'-C4'-O4' C3'-C4'-C5'-O5'	-3.8 (4) 175.2 (3)	C3'-C4'-O4'-C1' C3'-C4'-C5'-O5'	-18.3 (3) 175.2 (3)
N8-N9-C1'-O4' C1'-C2'-C3'-C4'	101.9 (4) 22.5 (4)	O3'-C3'-C4'-C5' O4'-C4'-C5'-O5'	113.1 (3) 54.9 (4)

Table 4 Hydrogen-bonding geometry (Å, °) for (II).

$D-H\cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdot \cdot \cdot A$	$D-\mathrm{H}\cdots A$
N6-H61···O5′i	0.86	2.12	2.870 (4)	145.9
$N6-H62\cdots Br7$	0.85	2.84	3.510(3)	136.4
$O3'-H3'1\cdots N1^{ii}$	0.82	2.21	2.828 (4)	131.9
$O5'-H5'\cdots N3^{iii}$	0.82	2.08	2.890 (4)	171.9

Symmetry codes: (i) $-x, \frac{1}{2} + y, 1 - z$; (ii) 1 + x, y, 1 + z; (iii) $1 - x, y - \frac{1}{2}, 1 - z$.

All H atoms were found in difference Fourier syntheses but were constructed in geometrically reasonable positions, with the exception of the amino H atoms. These were first refined with a common N-H distance and then fixed on the amino N atoms using a riding model. For all H atoms a common isotropic displacement parameter was refined. The absolute configurations were confidently proven by the diffraction experiment.

For both compounds, data collection: *XSCANS* (Siemens, 1996); cell refinement: *XSCANS*; data reduction: *SHELXTL* (Sheldrick, 1997a); program(s) used to solve structure: *SHELXS*97 (Sheldrick, 1997b); program(s) used to refine structure: *SHELXL*97 (Sheldrick, 1997b); molecular graphics: *SHELXTL*; software used to prepare material for publication: *SHELXTL*.

Supplementary data for this paper are available from the IUCr electronic archives (Reference: LN1089). Services for accessing these data are described at the back of the journal.

References

Flack, H. D. (1983). Acta Cryst. A39, 876-881.

IUPAC-IUB Joint Commission on Biochemical Nomenclature (1983). Eur. J. Biochem. 131, 9–15.

Klyne, W. & Prelog, V. (1960). Experientia, 16, 521-523.

Prusiner, P., Brennan, T. & Sundaralingam, M. (1973). *Biochemistry*, **12**, 1196–1202

Rao, S. T., Westhof, E. & Sundaralingam, M. (1981). Acta Cryst. A37, 421–425.
Rosemeyer, H., Zulauf, M., Ramzaeva, N., Becher, G., Feiling, E., Mühlegger, K., Münster, I., Lohmann A. & Seela, F. (1997). Nucleosides Nucleotides, 16, 871–878

Seela, F., Becher, G., Rosemeyer, H., Reuter, H., Kastner, G. & Mikhailopulo, I. A. (1999). Helv. Chim. Acta, 82, 105–124.

Seela, F., Ramzaeva, N. & Zulauf, M. (1997). Nucleosides Nucleotides, 16, 963–966.

Seela, F. & Zulauf, M. (1998). J. Chem. Soc. Perkin Trans. 1, pp. 3233–3239.

Seela, F. & Zulauf, M. (1999). *J. Chem. Soc. Perkin Trans.* 1, pp. 479–488. Seela, F., Zulauf, M., Kastner, G. & Reuter, H. (1999). *Acta Cryst.* C**55**, 1947–

Seela, F., Zulauf, M., Rosemeyer, H. & Reuter, H. (1996). J. Chem. Soc. Perkin Trans. 2, pp. 2373–2376.

Sheldrick, G. M. (1997a). SHELXTL. Release 5.1. Bruker AXS Inc., Madison, Wisconsin, USA.

Sheldrick, G. M. (1997b). SHELXL97 and SHELXS97. University of Göttingen, Germany.

Siemens (1996). *XSCANS*. Version 2.2. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.

Singh, P. & Hodgson, D. J. (1974). J. Am. Chem. Soc. 96, 5276–5278.

Sprang, S., Scheller, R., Rohrer, D. & Sundaralingam, M. (1978). J. Am. Chem. Soc. 100, 2867–2872.